A Phase 4 interventional study of budesonide/formoterol Turbuhaler 320/9µg and formoterol Turbuhaler 9µg in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 9 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-08-30.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 97th largest by enrollment of the 194 interventional ones that give a count, is one of 9 that started in 2007, is one of 19 in phase 4, and was the 23rd registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect on exercise tolerance, lung function and symptoms after treatment with Symbicort, Oxis or placebo in patients with severe chronic obstructive pulmonary disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
Drug: budesonide/formoterol Turbuhaler 320/9µg · Drug: formoterol Turbuhaler 9µg · Other: Placebo
Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
Drug: budesonide/formoterol Turbuhaler 320/9µg · Drug: formoterol Turbuhaler 9µg · Other: Placebo
Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily
Drug: budesonide/formoterol Turbuhaler 320/9µg · Drug: formoterol Turbuhaler 9µg · Other: Placebo
Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
Placebo, 1 inhalation twice daily
Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose
Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.
Time frame: Single measurement taken1 hour post-dose at the end of each 1-week treatment period
Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose
Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.
Time frame: Single measurement taken 6 hours post-dose at the end of each 1-week treatment period
Forced Expiratory Flow (FEV1) Pre-dose
The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.
Time frame: Pre-dose at the start of treatment and pre-dose after one week of treatment
Forced Vital Capacity (FVC) Pre-dose
The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.
Time frame: Pre-dose at the start of treatment and pre-dose after one week of treatment
Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment)
The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.
Time frame: Pre-dose at the start of treatment and pre-dose after one week of treatment
Peak Expiratory Flow (PEF) Before Morning Dose
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period.
Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Sleep Score
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms).
Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Breathlessness Score
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included.
Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Chest Tightness Score
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort).
Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Cough Score
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough).
Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Number of Inhalations of Reliever Medication
The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period.
Time frame: Daily diary data entered during the 1-week run-in or wash-out period and the subsequent 1-week treatment period
Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose
The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness).
Time frame: Single measurement performed at rest prior to exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose
The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).
Time frame: Single measurement performed after exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose
The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).
Time frame: Single measurement performed at rest prior to exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose
The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort). All patients with data are included.
Time frame: Single measurement performed after exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 1hour post-dose at the end of each 1-week treatment period
Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 1 hour post-dose at the end of each 1-week treatment period
Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 6 hous post-dose at the end of each 1-week treatment period
Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET)
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET
Treatment means from individual participant data.
Time frame: Single measurement obtained before exercise endurance test performed 6 hours post-dose at the end of each 1-week treatment period
SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score
Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data.
Time frame: Single measurement taken at the end of each 1-week treatment period
Patients were recruited in 12 centers in Germany and 12 centers in Switzerland.
| Milestone | Symbicort Then Formoterol Then Placebo | Formoterol Then Symbicort Then Placebo | Placebo Then Formoterol Then Symbicort |
|---|---|---|---|
| Started | 36 | 37 | 38 |
| Completed | 36 | 37 | 38 |
| Not completed | 0 | 0 | 0 |
| Milestone | Symbicort Then Formoterol Then Placebo | Formoterol Then Symbicort Then Placebo | Placebo Then Formoterol Then Symbicort |
|---|---|---|---|
| Started | 36 | 37 | 38 |
| Completed | 35 | 34 | 32 |
| Not completed | 1 | 3 | 6 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Study-specific discontinuation criteria | 0 | 1 | 4 |
| Milestone | Symbicort Then Formoterol Then Placebo | Formoterol Then Symbicort Then Placebo | Placebo Then Formoterol Then Symbicort |
|---|---|---|---|
| Started | 33 | 35 | 33 |
| Completed | 33 | 35 | 33 |
| Not completed | 0 | 0 | 0 |
| Milestone | Symbicort Then Formoterol Then Placebo | Formoterol Then Symbicort Then Placebo | Placebo Then Formoterol Then Symbicort |
|---|---|---|---|
| Started | 33 | 35 | 33 |
| Completed | 29 | 32 | 31 |
| Not completed | 4 | 3 | 2 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Study specific discontinuation criteria | 3 | 2 | 2 |
| Milestone | Symbicort Then Formoterol Then Placebo | Formoterol Then Symbicort Then Placebo | Placebo Then Formoterol Then Symbicort |
|---|---|---|---|
| Started | 29 | 30 | 33 |
| Completed | 29 | 29 | 33 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Study specific discontinuation criteria | 0 | 1 | 0 |
| Milestone | Symbicort Then Formoterol Then Placebo | Formoterol Then Symbicort Then Placebo | Placebo Then Formoterol Then Symbicort |
|---|---|---|---|
| Started | 29 | 29 | 33 |
| Completed | 29 | 29 | 33 |
| Not completed | 0 | 0 | 0 |
Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.
| Seconds | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 1 Hour Post-dose | 529 ± 377 | 441 ± 292 | 406 ± 306 |
Treatment means from individual patient data. Patients with only one EET value where excluded since this model, with patient and period as fixed factors, required data from at least two periods.
| Seconds | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Exercise Endurance Time (EET) at 75% of Peak Work Capacity With Cycle Ergometry 6 Hour Post-dose | 463 ± 312 | 408 ± 283 | 388 ± 306 |
The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Forced Expiratory Flow (FEV1) Pre-dose | 0.0830 ± 0.2480 | 0.0630 ± 0.2500 | -0.046 ± 0.1830 |
The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Forced Vital Capacity (FVC) Pre-dose | 0.060 ± 0.406 | 0.067 ± 0.407 | -0.094 ± 0.360 |
The mean of the changes for each patient between the pre-dose value at the start of treatment and the pre-dose value after one week of treatment.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Vital Capacity (VC) Pre-dose (Change From Pre-treatment to Treatment) | 0.105 ± 0.3600 | 0.089 ± 0.370 | -0.083 ± 0.371 |
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period.
| Liters/minute | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Peak Expiratory Flow (PEF) Before Morning Dose | 1.30 ± 32.70 | 5.60 ± 21.50 | -10.00 ± 27.00 |
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (symptoms did not cause a sleep problem) to 4 (did not sleep at all due to symptoms).
| Score on Scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Sleep Score | -1.70 ± 0.47 | -0.03 ± 0.47 | 0.11 ± 0.47 |
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any difficulty in breathing) to 4 (almost constant difficulties in breathing). All patients with data from both periods are included.
| Score on Scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Breathlessness Score | -0.12 ± 0.54 | -0.40 ± 0.46 | 0.15 ± 0.49 |
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of any discomfort) to 4 (almost constant discomfort).
| Score on a scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Chest Tightness Score | -0.08 ± 0.46 | -0.02 ± 0.47 | 0.17 ± 0.47 |
The change in average value for the run-in or wash-out period to the average value of the subsequent treatment period, with an ordinal scale of 0 (unaware of coughing) to 4 (never free of need to cough).
| Scores on a scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Cough Score | -0.11 ± 0.51 | -0.05 ± 0.50 | 0.10 ± 0.45 |
The change in average daily use for the run-in or wash-out period to the average daily use of the subsequent treatment period.
| Number of inhalations during 24 hours | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Number of Inhalations of Reliever Medication | -0.42 ± 1.51 | -0.36 ± 1.26 | 0.51 ± 1.33 |
The Borg CR10 Scale consists of 10-point score that the patients pointed to so as to indicate their level of dyspnea before and during exercise testing (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness. Patients are allowed to assign an even higher number depending on their perceived level of breathlessness).
| Scores on a scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Borg CR10 Score Before Exercise Endurance Time (EET) Performed 1 Hour Post-dose | 3.3 ± 3.2 | 3.4 ± 3.1 | 3.9 ± 3.5 |
The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).
| Scores on a scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Borg CR10 Score After Exercise Endurance Time (EET) Performed 1 Hour Post-dose | 11.5 ± 2.7 | 11.6 ± 2.9 | 11.4 ± 2.9 |
The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort).
| Scores on a scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Borg CR10 Score Before Exercise Endurance Time (EET) Performed 6 Hour Post-dose | 3.6 ± 3.2 | 3.4 ± 3.1 | 3.9 ± 3.5 |
The level of breathing discomfort experienced by patients, on a scale of 0 (no breathing discomfort at all) to \>10 (absolute maximum breathing discomfort). All patients with data are included.
| Scores on a scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Borg CR10 Score After Exercise Endurance Time (EET) Performed 6 Hours Post-dose | 11.5 ± 2.9 | 11.5 ± 3.1 | 11.8 ± 3.1 |
Treatment means from individual participant data.
| Liter | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 1 Hour Postdose | 2.06 ± 0.85 | 2.10 ± 0.82 | 1.97 ± 0.72 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Inspiratory Capacity (IC) Before Exercise Endurance Time (EET) Performed 6 Hours Post-dose | 2.12 ± 0.79 | 2.12 ± 0.80 | 1.85 ± 0.84 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Vital Capacity (VC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET) | 2.75 ± 0.72 | 2.73 ± 0.77 | 2.37 ± 0.66 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | 2.19 ± 0.61 | 2.18 ± 0.70 | 1.91 ± 0.58 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | 5.59 ± 1.69 | 5.66 ± 1.61 | 5.79 ± 1.64 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Residual Volume (RV) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | 4.83 ± 1.59 | 4.94 ± 1.62 | 5.13 ± 1.65 |
Treatment means from individual participant data.
| Liter | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 1 Hour Exercise Endurance Time (EET) | 7.58 ± 1.71 | 7.62 ± 1.68 | 7.45 ± 1.76 |
Treatment means from individual participant data.
| kilopascal | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 1 Hour Post-dose Exercise Endurance Time (EET) | 2.90 ± 1.66 | 2.98 ± 1.81 | 4.22 ± 2.29 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Vital Capacity (VC) (Body Plethysmography) Performed Before 6 Hour Exercise Endurance Time (EET) | 2.69 ± 0.730 | 2.64 ± 0.78 | 2.42 ± 0.71 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Inspiratory Capacity (IC) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET) | 2.14 ± 0.60 | 2.08 ± 0.69 | 1.92 ± 0.66 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Forced Respiratory Capacity (FRC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET) | 5.47 ± 1.65 | 5.49 ± 1.45 | 5.82 ± 1.88 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Residual Volume (RV) (Body Plethysmography) Performed Before 6 Hour Post-dose Exercise Endurance Time (EET) | 4.74 ± 1.63 | 4.79 ± 1.52 | 5.19 ± 1.92 |
Treatment means from individual participant data.
| Liters | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Total Lung Capacity (TLC) (Body Plethysmography) Performed Before 6 Hours Post-dose Exercise Endurance Time (EET) | 7.41 ± 1.68 | 7.37 ± 1.55 | 7.63 ± 2.00 |
Treatment means from individual participant data.
| Kilopascals | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Specific Airway Resistance (sRaw) (Body Plethysmography) Performed Before 6 Hours Post-dose EET | 3.06 ± 1.68 | 3.20 ± 2.02 | 4.12 ± 2.54 |
Score from a questionnaire, with scores ranging form 0 (perfect health) to 100 (worst possible state). Includes all patients with data.
| Scores on a scale | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| SGRQ-C (St. George's Respiratory Questionnaire for COPD Patients) Total Score | 51.7 ± 18 | 51.6 ± 19.2 | 54.5 ± 18.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort | — | 2/101 (2%) | 4/101 (4%) |
| Formoterol | — | 1/102 (1%) | 3/102 (2.9%) |
| Placebo | — | 1/104 (1%) | 6/104 (5.8%) |
| Event | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Wrist FractureInjury, poisoning and procedural complications | 1/101 | 0/102 | 0/104 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/101 | 1/102 | 1/104 |
| Event | Symbicort | Formoterol | Placebo |
|---|---|---|---|
| Chonic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 4/101 | 3/102 | 6/104 |
| Age Continuous(Year) | Entire Study Population |
|---|---|
| Mean | 63.7 (42 to 83) |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 27 |
| Male | 84 |
The record gives a start of Jul 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →